PF4 Polypeptide Immunoassay for Prothrombotic Thrombocytopenia Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively determine the risk of prothrombotic thrombocytopenia triggered by viral infections or vaccinations, which can lead to severe thrombotic events such as venous sinus thromboses and deep vein thromboses, due to the formation of autoantibodies against platelet factor 4 or viral spike proteins.
Innovation Solution
A method involving a polypeptide with at least 75% identity to the platelet factor 4 amino acid sequence is used to form complexes with antibodies in a sample, followed by an immunoassay to detect these antibodies and assess thrombocyte activation, thereby determining the risk of prothrombotic thrombocytopenia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to monitor thrombocyte count, then thrombocytopenia can be detected, but the risk of prothrombotic thrombocytopenia cannot be determined in advance
Solution Approach 1:
The invention performs preliminary detection of autoantibodies against PF4 before thrombotic events occur. By measuring antibody levels and calculating risk scores in advance, the method enables prophylactic intervention before severe thrombotic complications develop, resolving the timing issue between detection and prevention.
Solution Approach 2:
The invention uses autoantibody levels against PF4 as an intermediary marker to predict the risk of prothrombotic thrombocytopenia. Instead of directly monitoring thrombotic events or thrombocyte count changes, the method measures antibody presence and calculates a risk score, which serves as an early warning indicator for potential thrombotic risks.
2Measurement precision
If polypeptides with high sequence identity to PF4 are used in the assay, then detection specificity is improved, but cross-reactivity with viral spike proteins may increase
Solution Approach 1:
The invention uses polypeptides with at least 75% sequence identity to native PF4, preserving the critical epitope regions that autoantibodies recognize. This local quality preservation ensures high detection specificity for pathogenic autoantibodies while the controlled sequence similarity manages cross-reactivity with viral spike proteins.
Solution Approach 2:
The invention optimizes the sequence identity parameter of the polypeptide (at least 75% but not 100%) to balance detection sensitivity and specificity. By adjusting this parameter, the assay achieves high precision in detecting autoantibodies against PF4 while minimizing false positives from cross-reactivity with viral proteins that have lower sequence homology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the identification of high-affinity antibodies that can trigger prothrombotic thrombocytopenia, enabling prophylactic or therapeutic measures to prevent severe thrombotic events.
Implementation Method 1
contacting the first polypeptide according to (i) with a sample of a subject under suitable conditions for allowing the formation of a complex between polypeptide and antibodies which are present in the sample and capable of forming a complex with the first polypeptide
Data Source
AI summary
The invention relates to a method for determining whether a subject has an increased risk of developing a prothrombotic thrombocytopenia in response to a vaccination against a viral infection or in the event of a viral infection, said method comprising the steps of: providing a first polypeptide, comprising an amino acid sequence having at least 75% identity with the SEQ ID NO:1 or SEQ ID NO:2 (i); contacting the first polypeptide according to (i) with a sample from a subject under suitable conditions, in order to allow the formation of a complex between the polypeptide and antibodies present in the sample which are capable of forming the complex with the first polypeptide, where appropriate producing a complex of the first polypeptide and antibodies (ii).